MGI Tech’s DNBSEQ-T1+ Gains CE IVDR Certification for EU Market Entry
China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) announced that its latest mid-throughput...
Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million
China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake...
Simcere Pharma’s Quviviq Receives NMPA Approval for Insomnia Treatment
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) revealed that its marketing approval filing for Quviviq...
Sanofi and Regeneron Win FDA Approval for Dupixent in Bullous Pemphigoid Treatment
France major Sanofi (NASDAQ: SNY) and US-based biopharma Regeneron (NASDAQ: REGN) announced that Dupixent (dupilumab)...
Zai Lab’s Partner argenx Secures EU Approval for Vygart in CIDP Treatment
China-based Zai Lab Limited’s (NASDAQ: ZLAB, HKG: 9688) Dutch partner argenx SE (NASDAQ: ARGX) announced...
Harbour BioMed and Otsuka Pharma Collaborate Globally on BCMAxCD3 Bispecific T-cell Engager
China-based Harbour BioMed (HKG: 2142) has entered into a global strategic collaboration with Japan-headquartered Otsuka...
CanSino Biologics’ PCV13i Vaccine Gains NMPA Approval
China-based CanSino Biologics Inc., (HKG: 6185) announced that the National Medical Products Administration (NMPA) has...
Zhongsheng Pharma’s RAY1225 Enters Phase III Trial for Obesity/Overweight Treatment
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the initiation of the multi-center, randomized,...
Dizal’s Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its...
Shanghai Pharmaceuticals Receives Thai FDA Approval for Pregabalin Capsules
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that it has...
Wantai Biological Launches Phase III Trial for VZV-7D Varicella Vaccine
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation of...
MSD Initiates IDeate-Prostate01 Phase III Trial of Ifinatamab Deruxtecan for mCRPC
Merck, Sharp & Dohme (MSD, NYSE: MRK) this week announced the first patient dosing in...
Changchun BCHT Gains NMPA Approval for BK-01 Adjuvanted Influenza Vaccine
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) announced that it has received clinical trial...
NMPA’s CDE Reports 4,900 Clinical Trial Filings for Innovative Drugs in 2024
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released its...
Beijing Science Sun Pharma Inks RMB20M Drug Tech Transfer Pact for NeoAB33 Project
Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a Drug Technology Transfer Agreement with...
CDE Issues New Requirements for IND Applications of Innovative Drugs
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) this week...
ADVANZ PHARMA Acquires Bayer’s Testoviron Commercial Rights in Key Markets
UK-based ADVANZ PHARMA announced the acquisition of commercial rights to testoviron from German giant Bayer...
Medtide’s IPO Raises HKD 514 Million to Expand Global Peptide CRDMO Services
Hangzhou-based Medtide Inc., a leading Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides,...
Shanghai Innogen’s Diabetes Drug Patent for Efsubaglutide Alfa Fully Invalidated
Shanghai Innogen Pharmaceutical Technology Co., Ltd recently had its patent for efsubaglutide alfa (brand name:...
Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer’s Disease
China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II...